List of Medical Device Companies in Australia - 14

The Atmo Gas Capsule is a world first patented solution to accurately profile the gases within the gut, leading to better diagnosis and treatment of gastrointestinal disorders.

Atomo Diagnostics is a medical device manufacturer headquartered in Sydney, Australia with offices in South Africa and the United Kingdom. Atomo Diagnostics was established to capitalise on a core belief that healthcare products offering significantly improved levels of convenience, simplicity and user experience are disproportionately disruptive and have the potential to be very successful commercial market entrants. In 2013, Atomo introduced AtomoRapid, a range of safe, simple professional use tests that deliver fast and accurate results in both clinical and community settings. In 2014, AtomoRapid HIV won Best in Show at the Medical Device Excellence Awards (MDEA) and Atomo was named Australian Emerging Company of the Year for 2014 by Johnson & Johnson Innovation. Atomo is committed to increasing the early detection and ongoing treatment of infectious and chronic diseases by making testing safer, more accurate and more accessible. Visit our website, www.atomodiagnostics.com, for more information on our company and products.

Avania brings knowledgeable experts together to form a unique CRO that advances the research of medical devices, novel technology, and combination products across a wide range of therapeutic specialties. Our motivated team takes you from feasibility all the way through post-market trials. Our experts in data management and analytics, clinical trial design & execution, strategic consulting, regulatory, reimbursement, and more will provide you with customized, scalable solutions that optimize efficiencies and streamline the advancement of your medical technology. Your product is important, and your company deserves the team that has what it takes. It takes knowledge. It takes passion. It takes commitment. It takes Avania.

BCAL Diagnostics is an Australian-owned, ASX listed, biotechnology company. Since its establishment in 2010, BCAL Diagnostics has been striving to help identify health issues in women that is safe, accessible and cost effective.

Cardiex Limited (ASX:CDX) is a medical technology company listed on the ASX, focusing on non-invasive vascular health monitoring and digital biomarker solutions for cardiovascular disease management. The company specializes in technologies that measure arterial stiffness and central blood pressure, addressing global cardiovascular health challenges. Cardiex develops FDA-cleared medical devices and digital health solutions aimed at assessing cardiovascular risk, detecting early disease onset, and monitoring treatment efficacy. Its flagship product, the SphygmoCor® system, is recognized for measuring central aortic pressures and arterial stiffness. The company offers services such as clinical decision support, clinical trial solutions, remote patient monitoring, and research partnerships, targeting healthcare providers, clinical trials, researchers, and consumers. With a commitment to reducing the global burden of cardiovascular disease, Cardiex has seen significant revenue growth and has established partnerships to enhance wearable technology adoption. Its product lineup includes the CONNEQT Pulse, a connected vascular biometric monitor, and the Arty™ App for remote patient monitoring, among others.

Ellume is an Australian based Health Technology company that develops and manufactures connected real-time diagnostics for doctors and consumers. We achieve this by combining next-generation quantum dot diagnostics with connected care technologies. Our products are distinguished by their simplicity of design, ease of use, rapid time to result and connectivity. To learn more about Ellume, visit our website at www.ellumehealth.com.

Ferronova is an innovative medical device company, which has brought together a patented magnetic probe from the University of South Australia and iron magnetic nanoparticle technology from Victoria University of Wellington, to produce an advanced diagnostic system to improve the detection of cancer metastases. Ferronova has research collaborations with UniSA Future Industries Institute, the University of Sydney, and the University of New South Wales. Founded in 2016, Ferronova is backed by Uniseed, Artesian Ventures, ASX-listed investment group Powerhouse Ventures, PAN Ventures, UniSA Ventures and Wellington UniVentures. The South Australian government and Australian government have provided grant funding to develop the technology.

Invion is a clinical-stage life-sciences company that is leading the global clinical development of the Photosoft™ technology for the treatment of cancers. Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of Photosoft™. The appointment has been made by technology licensor, The Cho Group, a Hong Kong based group that has funded and successfully commercialised a number of unique and advanced technologies. Via an R&D services agreement between the two entities, the research and clinical trials of Photosoft™ are funded by The Cho Group. Invion has an alliance with leading Australian medical research institute, Hudson Institute of Medical Research, for the Photosoft™ research program.

LBT Innovations is a medical technology company that utilizes artificial intelligence to deliver automation in healthcare through a patent-protected machine learning and intelligent imaging platform.

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy. OncoSil Medical's lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.

An RPM Business Augmented by R&D Respiri Limited (ASX:RSH, OTCQB:RSHUF) is a pioneering presence in the Remote Patient Monitoring (RPM) and MedTech sectors. The company uses its innovative respiratory technology with a disruptive business model as an RPM provider to offer the only RPM program for respiratory disorders. As a differentiated RPM provider, Respiri's mission is to improve health outcomes for patients with chronic diseases from cardiovascular, diabetes, obesity and, exclusively, respiratory disease. Respiri's globally unique medical device and its Remote Patient Monitoring services empower healthcare organisations to take action from patient data when needed, not only when scheduled. Respiri is strategically positioned to revolutionise chronic disease management globally and is focused on the US market, where RPM services are reimbursed by Current Procedural Terminology (CPT) Code reimbursement.

Synchron is a Brain Computer Interface company based in Campbell, California and Melbourne, Australia. We are developing minimally-invasive technology for safe and rapid implantation of miniaturized electronic medical devices with broadband capability.

Universal Biosensors Inc (UBI) is a global biosensor company and a world leader in electrochemical cell technology. UBI's ambition is to utilize its patented biosensor technology to develop a diverse range of biosensor test strips used in our hand-held portable analyzers; for cost effective, effortless, and accurate detection of analytes of interest, within many industries including human health, animal health, environmental, and agriculture. UBI is a USA Delaware company listed on the Australian Securities Exchange (ASX:UBI) and operates from its head office, manufacturing facility, and research laboratory in Melbourne, Victoria, Australia. In 2021, UBI successfully launched its unique handheld wine analyzer called Sentia™ with an initial test to measure free SO2 , and subsequently in 2022, tests for monitoring malic acid and glucose throughout the wine production process (more tests in the pipeline are due for release in late 2022). In 2022, UBI launched Xprecia Prime™ in the EU and UK, the next-generation blood coagulation analyzer which replaces Xprecia Stride™. Xprecia Prime™ is due for launch in the US in 2023. UBI is due to launch Petrackr™ in late 2022/early 2023, a veterinary blood glucometer to monitor diabetes in cats and dogs. These products will complement UBI's existing Canadian blood testing laboratory Hemostasis Reference Lab (HRL).

About Vestech Medical Device innovation and commercialisation is fraught with risk, missteps and wastage. Navigating the successful passage of a device from invention to commercial success is Vestech's area of expertise. Understanding the landscape, working with innovators and providing collaborative advice are key components of our day to day activities. Experience & Process When it comes to Medical Device development and commercialisation, nothing beats experience. Vestech has that hands on experience and more. Vestech and its team have been in the field of medical device commercialisation for more than 30 years. During that time Vestech has accumulated direct and personal experience in the following areas: The technical aspects of device design The regulatory requirements Intellectual property protection Liaising with tertiary institutions Business planning Reimbursement strategies Export development International regulations and systems Capital raising Listed entities management Legal requirements Human resource development Industry organisation engagement Federal and state policy development and lobbying Project management Exit strategies During the realisation of a medical device project, Vestech works with Australia's top specialist vendors and consultants to assure a first class result. Vestech's connections within Australia and Internationally have been built up and tested over decades to ensure "no surprises" delivery.